Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

TXGTXG
Showing 8 of 28 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in 10x Genomics Inc Class A

CITADEL ADVISORS LLC holds 2.8M shares of TXG (10x Genomics Inc Class A), worth $106.6M as of 2026-Q2. The position was increased (+273.7% shares). TXG represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$106.6M

Current Shares

2.8M

Total Value Change

+$43.8M

Total Shares Change

-757

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2.8M
+273.7%
$106.6M0.0%$38.34
48
2026-Q1
Increased
743,734
+468.5%
$15.8M0.0%$22.62
45
2025-Q4
New
130,820
-
$2.1M0.0%$16.29
36
2025-Q3
Exited
0
-100.0%
$00.0%$11.34
0
2025-Q2
Decreased
195,944
-81.6%
$2.3M0.0%$11.73
0
2025-Q1
Decreased
1.1M
-47.0%
$9.3M0.0%$9.16
0
2024-Q4
Decreased
2M
-27.8%
$28.8M0.0%$14.35
0
2024-Q3
Increased
2.8M
+731.4%
$62.8M0.0%$22.67
48

Other major holders of TXG: BAILLIE GIFFORD & CO, ARK Investment Management LLC, FMR LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used